Virtus LifeSci Biotech Clinical Trials ETF
16 hedge funds and large institutions have $6.15M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$712K | |
| 2 | +$606K | |
| 3 | +$333K | |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$73.9K |
| 5 |
Morgan Stanley
New York
|
+$34.2K |
Top Sellers
| 1 | -$1.04M | |
| 2 | -$440K | |
| 3 | -$304K | |
| 4 |
BAAM
Baker Avenue Asset Management
San Francisco,
California
|
-$254K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$20.3K |